What SK Capital Partners does

SK Capital Partners is a sector-focused private investment firm founded in 2007 and headquartered in New York, with operations across North America, Europe, Asia, and emerging markets. The firm invests exclusively in three adjacent verticals — material sciences, specialty ingredients, and life sciences — through two distinct fund programs: Flagship (upper mid-sized and large companies) and Catalyst (lower middle market, established 2019). SK Capital pursues control buyouts, recapitalizations, growth equity investments, and synergistic cross-portfolio transactions, partnering with founders and existing owners who retain equity participation.

The firm's competitive position rests on the deep domain specialization of its roughly 80–90 team members, who collectively hold decades of operating, investing, and technical experience across chemistry, material sciences, and life sciences. SK Capital does not develop proprietary technology; its product is capital plus sector knowledge plus an institutionalized Portfolio Excellence function that supports operational improvement, commercial effectiveness, and organizational development at portfolio companies. The firm has raised seven funds with over $9 billion in cumulative capital commitments (as of December 31, 2025), manages 20+ portfolio companies that collectively generate approximately $10 billion in annual revenue, and has executed both build-up roll-ups (Addivant/SI Group, Noramco+Extractas+Purisys) and platform extensions (Specialty Ingredients platform comprising J&K Ingredients, Brothers International, Spectra Confectionery, Florachem).

Revenue is generated through standard private equity fund economics — recurring management fees on committed or invested capital and episodic carried interest on realizations — supplemented by transaction fees and monitoring fees across the portfolio. The firm's distribution model is direct: deal flow originates from team relationships with management teams, boards, owners, and investment bankers rather than intermediated sourcing. Recent realizations include the Noramco/Extractas/Purisys sale to Siegfried (May 2026), Phoenix Flavors & Fragrances to Turpaz Industries (May 2026, $95M + $5M earnout), Isolatek International to Catchment Capital (June 2026), and the Apotex IPO on the TSX (June 2026) — demonstrating active portfolio turnover alongside continued platform acquisitions such as Brothers International (April 2026) and the EUR 1.5B+ majority stake in Swixx BioPharma (June 2026).

Name

SK Capital Partners

Legal name

SK Capital Partners, LP

Website

https://skcapitalpartners.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

SK Capital Partners is a sector-focused private equity firm founded in 2007 that invests in material sciences, specialty ingredients, and life sciences companies through Flagship and Catalyst strategies, managing over $9 billion across 20+ portfolio companies.

Ownership category

akta.pro rank

Product category

Private Equity Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Large-Cap / Mega-Fund Buyout (FSANABAA)

Keywords

• Sector-focused private equity
• Specialty chemicals investment
• Life sciences private equity
• Middle market buyouts
• Specialty ingredients investment

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Private Equity Fund Management: SK Capital generates returns through private equity investments in portfolio companies, pursuing control buyouts, recapitalizations, and growth equity investments. The firm manages multiple funds (Flagship and Catalyst strategies) and generates management fees and carried interest from their funds.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

SK Capital Partners is a private investment firm that pursues control buyouts, recapitalizations, and growth equity investments in the material sciences, specialty ingredients, and life sciences sectors. The firm operates two strategies—Flagship funds targeting upper mid-sized and large companies, and Catalyst funds (established 2019) dedicated to lower middle market companies—with 7 funds raised and over $9 billion in capital commitments since inception.

Product overview

SK Capital Partners operates two distinct private equity investment fund strategies: Flagship funds targeting upper mid-sized and large companies, and Catalyst funds (established 2019) focused on the lower middle market. Both strategies concentrate on three core sectors—material sciences, specialty ingredients, and life sciences—leveraging deep industry expertise, operational knowledge, and extensive networks to drive transformational growth and improvement in portfolio companies. The firm has raised 7 funds with over $9 billion in capital commitments and manages approximately $8.5 billion in aggregate commitments as of recent reports, with portfolio companies collectively generating approximately $10 billion in annual revenue.

Differentiator

Problem solved

Functional benefit

Products and services

• SK Capital Flagship Funds Private equity fund strategy targeting upper mid-sized and large companies for transformational growth and operational improvement in material sciences, specialty ingredients, and life sciences sectors.
• SK Capital Catalyst Funds Private equity fund strategy dedicated to lower middle market companies in material sciences, specialty ingredients, and life sciences, with a hands-on value creation approach.

Quantifiable outcome

• Over $9 billion in capital commitments raised
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• KKR: Mega-fund PE firm with significant chemicals and life sciences investing activity. While much larger, KKR competes with SK Capital for similar specialty chemicals control-buyout opportunities in the upper-middle market.
• Apollo Global Management: Mega-fund alternative asset manager with deep specialty chemicals and materials investing history. Overlaps with SK Capital on chemicals and life sciences deal sourcing, though Apollo operates at much larger AUM.
• Carlyle Group: Large-cap diversified PE firm with active healthcare and industrial chemicals investing. SK Capital partnered with Carlyle on the Genetix Biotherapeutics acquisition, evidencing direct co-investment activity.

Direct peers

• Wynnchurch Capital: Middle-market PE firm specializing in complex carve-outs, recapitalizations, and operational turnarounds in industrial and specialty manufacturing — directly comparable to SK Capital's transformation playbook.
• Bain Capital: Global private equity firm with a dedicated Life Sciences vertical and a sector-specialist approach that overlaps directly with SK Capital's three-sector focus. Bain Capital Life Sciences also co-invested with SK on Swixx Biopharma.
• Advent International: Large-cap global private equity firm with significant chemicals and life sciences investing experience. Comparable AUM scale and similar control-buyout orientation to SK Capital's Flagship strategy.
• Centerbridge Partners: Multi-strategy private investment firm with significant chemicals, materials, and healthcare investing. Comparable AUM size and similar middle/large-market buyout approach to SK Capital's Flagship.
• Audax Group: Middle-market private equity firm focused on buyouts across industrial, healthcare, and specialty sectors. Closely mirrors SK Capital's Catalyst strategy orientation and sector breadth.
• Cerberus Capital Management: Multi-strategy private investment firm with active industrial and specialty chemicals portfolio. Operates in the same AUM bracket and pursues similar control-buyout opportunities in SK's core sectors.
• Lone Star Funds: Global private equity firm focused on control investments and special situations in industrial, chemicals, and financial sectors. Comparable middle-market, sector-tilted approach with global deal sourcing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SKCapital
• LinkedInlinkedin.com/company/sk-capital-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries36 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A34 records

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SK Capital Partners